全球难治性高血压患病率:320万患者数据的荟萃分析
该研究系统检索截至2017年9月的文献,纳入91项研究、共3 207 911例服用降压药的高血压患者,采用随机效应模型估计难治性高血压患病率。结果显示真性难治性高血压患病率为10.3%,表观难治性为14.7%,假性难治性为10.3%;慢性肾病患者真性难治性患病率最高(22.9%)。
要点
- 真性难治性高血压全球患病率为10.3%,低于表观难治性14.7%。
- 假性难治性高血压占10.3%,需用动态血压监测排除白大衣效应。
- 慢性肾病患者真性难治性高血压患病率高达22.9%。
核心结论
- 真性难治性高血压患病率较高,但低于表观难治性高血压,提示需排除假性难治性高血压的原因。
- 慢性肾病患者难治性高血压负担最重。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、Web of Science和Global Index Medicus从建库至2017年9月30日的文献。
- 纳入91项研究,汇总样本为3 207 911例服用降压药的高血压患者。
- 采用随机效应模型估计患病率,异质性通过Cochran Q统计量的χ²检验评估。
主要发现
- 64项研究(70%)仅使用诊室血压测量。
- 在一般治疗高血压人群中,真性难治性、表观难治性和假性难治性高血压患病率分别为10.3%(95%CI 7.6%至13.2%)、14.7%(95%CI 13.1%至16.3%)和10.3%(95%CI 6.0%至15.5%)。
- 真性难治性高血压患病率在慢性肾病患者为22.9%(95%CI 19.1%至27.0%),肾移植患者为56.0%(95%CI 52.7%至59.3%),老年患者为12.3%(95%CI 1.7%至30.5%)。
临床怎么用
- 对表观难治性高血压患者应使用动态血压监测排除白大衣高血压等假性难治原因。
- 慢性肾病患者应重点关注难治性高血压的筛查与管理。
局限性
- 多数研究(64项,70%)仅使用诊室血压测量,可能影响假性难治性高血压的识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We conducted the first systematic review and meta-analysis to estimate the specific prevalence of apparent treatment-resistant, pseudo-resistant and true-resistant hypertension among treated patients with hypertension globally. METHODS: We conducted a search in PubMed, EMBASE, Web of Science and Global Index Medicus to identify articles published from inception to 30 September 2017, and searched the reference list of retrieved articles. We used a random-effects model to estimate the prevalence of resistant hypertension across studies and heterogeneity was assessed via the χ² test on Cochran's Q statistic. RESULTS: We included 91 studies published between 1991 and 2017 reporting data of a pooled sample of 3 207 911 patients with hypertension on antihypertensive drugs globally. Most of the studies (n=64, 70%) only used office blood pressure (BP) measurement. In the general, population of treated patients with hypertension, the prevalence of true-resistant, apparent treatment-resistant and pseudo-resistant hypertension were 10.3% (95% CI 7.6% to 13.2%), 14.7% (95% CI 13.1% to 16.3%) and 10.3% (95% CI 6.0% to 15.5%). The prevalence of true-resistant hypertension was 22.9% (95% CI 19.1% to 27.0%), 56.0% (95% CI 52.7% to 59.3%) and 12.3% (95% CI 1.7% to 30.5%) in chronic kidney disease, renal transplant and elderly patients, respectively. CONCLUSIONS: This study shows a high prevalence of true-resistant hypertension. This prevalence is lower than that of apparent treatment-resistant hypertension, demonstrating the importance to exclude causes of pseudo-resistant hypertension including white-coat hypertension with the use of ambulatory BP measurement. The burden of resistant hypertension is highest in patients with chronic kidney disease. New treatments for resistant hypertension are highly needed, considering the disastrous complications of the disease.
引用
- Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2018. PMID: 30087099. doi:10.1136/heartjnl-2018-313599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。